iBio (IBIO)

• Market cap: $20.4M
• 1 day: 2.29%
• 5 days: -12.55%
• 1 month: -27.83%
• 3 months: 8.25%
• 6 months: 3.72%
• Year to date: 61.59%
• 1 year: -57.12%
• 5 years: -95.99%
• 10 years: -99.96%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Employees: 16

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

11% more funds holding

Funds holding: 28 [Q2] → 31 (+3) [Q3]

2% more capital invested

Capital invested by funds: $5.68M [Q2] → $5.79M (+$106K) [Q3]

1.06% less ownership

Funds ownership: 31.23% [Q2] → 30.17% (-1.06%) [Q3]

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6